Please take a second andVOTE for Detroit’s Children’s Hospitala click goes a long way for Sickle Cell. Let’s do this, Detroit’s a bit behind Houston and voting ends today.
To honor Tayshaun Prince on for his Birthday(Feb 28th), here is his 24 seconds segment.
^okay thank-you…it’s just that when i was waiting for the game to come on…my mom wanted to measure me ? then when i came back i just saw the end of it when he was saying something about Jessica Alba and i just got soo mad, lol
LET’S GO PISTONS AND LET’S GET THAT SHIP!!!!!!!!!!!!!!!!!!!!!!!!!!! 2007-2008 IT’S OUR TIME!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
ALL BOUT DETROIT BABY!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
i hate tayshaun ever since i seen how he really was at a meet n greet with not siging autographs for little kids and hurrying them up for pictures hes a complete ass and wouldnt mind seeing him leave..ur all fooled if u think hes a nice guy..hes not..now mcdyess ive met alot he ust to come into my store alot hes a really nice guy, but tayshaun just a jerk.
actually when i went to the game with need4sheed…tay came over and said hello and shaked my hand (i think he did it because he thought i was one of the kids that was in the kids for ‘Tay’s Town’) any tay seems really nice. But i would really want 2 meet Rodney and Amir…oh boy that would be some day.
LET’S GO PISTONS AND LET’S GET THAT SHIP!!!!!!!!!!!!!!!!!!!!!!!!!!! 2007-2008 IT’S OUR TIME!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
ALL BOUT DETROIT BABY!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
I would like to make you aware that there is a non-toxic viable treatment for sickle cell in the world, unfortunately it is not available in the U.S.. Through awareness there may come availability for those who so desperately need it. All it is going to take is the effort of a few individuals, patients and doctors to make this drug a reality in the U.S. sooner than later. Although this drug was developed in Nigeria, the man behind it, Dr. Ramesh Pandey is a distinguished biochemist who has worked for the National Cancer Institute’s (NCI) Frederick Cancer Research Center as a Senior Scientist, Head of the Chemistry Section, Abbott Pharmaceuticals and produced the first commercially viable generic version of Vancomycin for Lyphomed Inc., a Visiting Professor at the Waksman Institute of Microbiology at Rutgers, the State University of New Jersey, holds patents for biotechnology analysis and rare drug production processes. He also holds several US and international patents for paclitaxel and its new analogs. He is a member of the Editorial Board of the International Journal of Antibiotics and of several professional societies. He has been awarded several grants from NASA, NCI and NIH. The drug NICOSAN has been granted Orphan Drug Status by both the FDA and E.U..
There is a relatively new treatment for sickle cell being produced in Nigeria by an American company called NICOSAN®, it’s proprietary name is NIPRISAN® . It was developed on the premise of traditional Nigerian plant based medicinal practices for the treatment of sickle cell disease.
It has been tested through phase IIb clinical trials and found to be highly efficacious. Phase III trials have yet to be completed however it was approved for sale in Nigeria based on phase IIb trials and toxicity studies which showed it to be safe and non-toxic.
Double-blind, placebo-controlled, randomised cross-over clinical trial of NIPRISAN® in patients with Sickle Cell Disorder
This drug is a major advancement in the treatment of sickle cell disease unfortunately it is not available in the U.S.. Although the compound has been granted orphan drug status by the FDA and the regulatory body of the European Union, to date investigational drug applications for the approval process have yet to be submitted. Getting a drug approved in either area is extremely expensive. Until there is funding available to proceed with the FDA and EU applications it will be difficult for non-Nigerians to obtain the drug.
I do say difficult but it is not impossible. If you have a hematologist or hemoncologist who is willing to put fourth the effort there are special dispensations available through the FDA for the importation of unapproved drugs on a compassionate use basis.
“Expanded access program (EAP). EAPs are typically designed to provide widespread access to a drug that has proven efficacy in clinical trials but is still awaiting FDA approval. They’re similar to standard clinical trials with a specific treatment plan and certain FDA requirements, but they have looser patient eligibility criteria. More than 23,000 U.S. cancer patients enrolled in an EAP for Iressa before it was FDA-approved, for example.”
“Single patient use. This program offers an experimental drug to an individual patient, rather than a group. The FDA approves these uses on a case-by-case basis. Decisions are based on other treatments already available and information about the drug’s efficacy and potential toxicities.”
To date I have no knowledge that anyone has sought any single use or expanded access from the FDA for Nicosan. Unfortunately regardless of the dissemination of this information thus far no one has put forth the effort to obtain the drug for use.
If just one person would start the ball rolling with a caring and concerned medical practitioner it could open up the drug for wide spread use by tens of thousands of patients across the U.S. Unfortunately thus far the general response I receive is that people don’t believe that their physician would be interested in going to this sort of effort nor do they themselves seem to be inclined to seek the use of a treatment that could potentially end their crises.
There has to be at least one physician out there who has enough care and concern for his patients to be willing to put forth the effort necessary to obtain this medication legally. I urge anyone who is effected by sickle cell to approach their physicians with this information and attempt to obtain this treatment not only for themselves but for all patients who could potentially benefit from it’s use.
We already know the benefits of the treatments available in the U.S. and the E.U.. In many cases they are only marginally effective or in the case of hydroxyurea cause side effects so serious that many choose not to use it as treatment. Here we have an opportunity to use a treatment that has been shown to be highly effective, eradicating crises in the majority of patients and reducing crises by 50% in the most refractory cases.
Although the clinical trial group was what the casual reader might interpret as quite small it is common for drugs which fall into the orphan drug category to use small sample groups. Many orphan drugs have been approved based on very small phase II and phase IIb clinical trials in the U.S. In the case of FDA fast track status, a drug may be approved during phase II trials if the drug shows significant advantage over current approved therapies for life threatening illness.
Fast Track Designation is a program that, if granted, is designed to facilitate the development and expedite the review of new drugs, thereby allowing the FDA to approve drugs used to treat a serious condition or a life-threatening disease with less safety data following the conclusion of phase II studies, rather than phase III, the normal practice.
The main criterion for a Fast Track Designated drug is the potential to treat a life-threatening illness or fill a major unmet medical need. Fast Track may be submitted with the IND or at any time during the clinical development of the drug. The Fast Track designation may allow a company’s application to follow Priority Review, Standard Review, or a Rolling Review of the application.
Nicosan by Western standards is an extremely inexpensive drug. It is available in Nigeria without prescription at $23/month for adults and child doses at $18/month.
Here is a link to the company and product website.
I sincerely hope that you find this information helpful. I would encourage you to forward and post this information to any person, blog or website where persons effected by sickle cell anemia can have access to this information.
Feel free to write me with any questions you may have.
Happy B-Day Tayshaun. We are all supporting you. Happy 10th birthday. LOL!
oh yeah he gotta stay young 😀
LET’S GO PISTONS AND LET’S GET THAT SHIP!!!!!!!!!!!!!!!!!!!!!!!!!!! 2007-2008 IT’S OUR TIME!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
ALL BOUT DETROIT BABY!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
hey if anyone say the ’24 Seconds with Rodney Stuckey’ can someone recap on what he said ?
LET’S GO PISTONS AND LET’S GET THAT SHIP!!!!!!!!!!!!!!!!!!!!!!!!!!! 2007-2008 IT’S OUR TIME!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
ALL BOUT DETROIT BABY!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
I have Rodney’s coming, just haven’t posted it yet.
^okay thank-you…it’s just that when i was waiting for the game to come on…my mom wanted to measure me ? then when i came back i just saw the end of it when he was saying something about Jessica Alba and i just got soo mad, lol
LET’S GO PISTONS AND LET’S GET THAT SHIP!!!!!!!!!!!!!!!!!!!!!!!!!!! 2007-2008 IT’S OUR TIME!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
ALL BOUT DETROIT BABY!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
i hate tayshaun ever since i seen how he really was at a meet n greet with not siging autographs for little kids and hurrying them up for pictures hes a complete ass and wouldnt mind seeing him leave..ur all fooled if u think hes a nice guy..hes not..now mcdyess ive met alot he ust to come into my store alot hes a really nice guy, but tayshaun just a jerk.
hey.. detroit is in the lead.
awesome for sharing this natalie
actually when i went to the game with need4sheed…tay came over and said hello and shaked my hand (i think he did it because he thought i was one of the kids that was in the kids for ‘Tay’s Town’) any tay seems really nice. But i would really want 2 meet Rodney and Amir…oh boy that would be some day.
LET’S GO PISTONS AND LET’S GET THAT SHIP!!!!!!!!!!!!!!!!!!!!!!!!!!! 2007-2008 IT’S OUR TIME!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
ALL BOUT DETROIT BABY!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
I loved that. That’s the most I’ve heard Tayshaun talk since he came here,lol. I loved his expression and enthusiam. 🙂
DETROIT HOSPITAL WON 🙂 Nice stuff guys!! Well done
NICOSAN for the Treatment of Sickle Cell Disease
I would like to make you aware that there is a
non-toxic viable treatment for sickle cell in the
world, unfortunately it is not available in the U.S..
Through awareness there may come availability for
those who so desperately need it. All it is going to
take is the effort of a few individuals, patients and
doctors to make this drug a reality in the U.S. sooner
than later. Although this drug was developed in
Nigeria, the man behind it, Dr. Ramesh Pandey is a
distinguished biochemist who has worked for the
National Cancer Institute’s (NCI) Frederick Cancer
Research Center as a Senior Scientist, Head of the
Chemistry Section, Abbott Pharmaceuticals and
produced the first commercially viable generic version
of Vancomycin for Lyphomed Inc., a Visiting Professor
at the Waksman Institute of Microbiology at Rutgers,
the State University of New Jersey, holds patents for
biotechnology analysis and rare drug production
processes. He also holds several US and international
patents for paclitaxel and its new analogs. He is a
member of the Editorial Board of the International
Journal of Antibiotics and of several professional
societies. He has been awarded several grants from
NASA, NCI and NIH. The drug NICOSAN has been granted
Orphan Drug Status by both the FDA and E.U..
There is a relatively new treatment for sickle cell being
produced in Nigeria by an American company called NICOSAN®,
it’s proprietary name is NIPRISAN® . It was developed on
the premise of traditional Nigerian plant based medicinal
practices for the treatment of sickle cell disease.
It has been tested through phase IIb clinical trials and
found to be highly efficacious. Phase III trials have yet
to be completed however it was approved for sale in Nigeria
based on phase IIb trials and toxicity studies which showed
it to be safe and non-toxic.
Double-blind, placebo-controlled, randomised cross-over
clinical trial of NIPRISAN® in patients with Sickle Cell
Disorder
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B7GVW-4DS346T-1S&_user=10&_rdoc=1&_fmt=&_orig=search&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=211981d545303693affebb8c012d2cac
Efficacy of Niprisan in the prophylactic management of
patients with sickle cell disease
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6VS8-43DFJCH-G&_user=10&_rdoc=1&_fmt=&_orig=search&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=10528ecbab3ec7e977301fb9f2688ef6
NIPRISAN — Nix-0699 Toxicity Studies
http://www.biospace.com/news_story.aspx?StoryID=15890720&full=1
Niprisan (Nix-0699) improves the survival rates of
transgenic sickle cell mice under acute severe hypoxic
conditions
http://www.blackwell-synergy.com/doi/abs/10.1046/j.1365-2141.2003.04536.x?journalCode=bjh
NIPRISAN Case, Nigeria
A Report for GenBenefit (2007)
http://www.theparliament.com/NR/rdonlyres/F46A1A12-0A1A-41DA-9F5D-A11486CA9BFA/0/Nigerian_Case.pdf
This drug is a major advancement in the treatment of sickle
cell disease unfortunately it is not available in the U.S..
Although the compound has been granted orphan drug status
by the FDA and the regulatory body of the European Union,
to date investigational drug applications for the approval
process have yet to be submitted. Getting a drug approved
in either area is extremely expensive. Until there is
funding available to proceed with the FDA and EU
applications it will be difficult for non-Nigerians to
obtain the drug.
I do say difficult but it is not impossible. If you have a
hematologist or hemoncologist who is willing to put fourth
the effort there are special dispensations available
through the FDA for the importation of unapproved drugs on
a compassionate use basis.
“Expanded access program (EAP). EAPs are typically designed
to provide widespread access to a drug that has proven
efficacy in clinical trials but is still awaiting FDA
approval. They’re similar to standard clinical trials with
a specific treatment plan and certain FDA requirements, but
they have looser patient eligibility criteria. More than
23,000 U.S. cancer patients enrolled in an EAP for Iressa
before it was FDA-approved, for example.”
“Single patient use. This program offers an experimental
drug to an individual patient, rather than a group. The FDA
approves these uses on a case-by-case basis. Decisions are
based on other treatments already available and information
about the drug’s efficacy and potential toxicities.”
http://www.curetoday.com/backissues/v3n3/departments/specialreport/index.html
To date I have no knowledge that anyone has sought any
single use or expanded access from the FDA for Nicosan.
Unfortunately regardless of the dissemination of this
information thus far no one has put forth the effort to
obtain the drug for use.
If just one person would start the ball rolling with a
caring and concerned medical practitioner it could open up
the drug for wide spread use by tens of thousands of
patients across the U.S. Unfortunately thus far the general
response I receive is that people don’t believe that their
physician would be interested in going to this sort of
effort nor do they themselves seem to be inclined to seek
the use of a treatment that could potentially end their
crises.
There has to be at least one physician out there who has
enough care and concern for his patients to be willing to
put forth the effort necessary to obtain this medication
legally. I urge anyone who is effected by sickle cell to
approach their physicians with this information and attempt
to obtain this treatment not only for themselves but for
all patients who could potentially benefit from it’s use.
We already know the benefits of the treatments available in
the U.S. and the E.U.. In many cases they are only
marginally effective or in the case of hydroxyurea cause
side effects so serious that many choose not to use it as
treatment. Here we have an opportunity to use a treatment
that has been shown to be highly effective, eradicating
crises in the majority of patients and reducing crises by
50% in the most refractory cases.
Although the clinical trial group was what the casual
reader might interpret as quite small it is common for
drugs which fall into the orphan drug category to use small
sample groups. Many orphan drugs have been approved based
on very small phase II and phase IIb clinical trials in the
U.S. In the case of FDA fast track status, a drug may be
approved during phase II trials if the drug shows
significant advantage over current approved therapies for
life threatening illness.
Fast Track Designation is a program that, if granted, is
designed to facilitate the development and expedite the
review of new drugs, thereby allowing the FDA to approve
drugs used to treat a serious condition or a
life-threatening disease with less safety data following
the conclusion of phase II studies, rather than phase III,
the normal practice.
The main criterion for a Fast Track Designated drug is the
potential to treat a life-threatening illness or fill a
major unmet medical need. Fast Track may be submitted with
the IND or at any time during the clinical development of
the drug. The Fast Track designation may allow a company’s
application to follow Priority Review, Standard Review, or
a Rolling Review of the application.
http://www.fda.gov/CbER/gdlns/fsttrk.pdf
Nicosan by Western standards is an extremely inexpensive
drug. It is available in Nigeria without prescription at
$23/month for adults and child doses at $18/month.
Here is a link to the company and product website.
http://xechemnigeria.com/products.htm
I sincerely hope that you find this information helpful. I
would encourage you to forward and post this information
to any person, blog or website where persons effected by
sickle cell anemia can have access to this information.
Feel free to write me with any questions you may have.
NicosanForSickleCell@yahoo.com